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Abstract
The mechanisms by which glucocorticoids (GC) regulate annexin I (ANXA1) secretion in different cells are still a matter of
debate. The aims of this study were to evaluate the ability of dexamethasone (Dex) to induce ANXA1 secretion and to inves-
tigate the roles of the intracellular free Ca2+ concentration ([Ca2+]
i
), and of the GC receptor, on that process. For this purpose,
the human immature lymphoblastic CCRF-CEM cell line was used. Treatment of the cells with Dex, for up to 4 h, significantly
reduced the intracellular content of ANXA1 and increased the amount of this protein bound to the outer surface of the plasma
membrane, whereas exposure of cells to Dex, for 12 h, induced the synthesis of ANXA1. At the same short time periods, Dex
also induced a significant increase in the [Ca2+]
i
. Incubation of the cells with BAPTA-AM (10 µM), a cell-permeant high affin-
ity Ca2+ chelator, completely inhibited Dex-induced ANXA1 secretion. Furthermore, the Ca2+ ionophore, ionomycin, alone
induced ANXA1 cleavage, but not its secretion. Additionally, we used brefeldin A to investigate the involvement of the clas-
sical endoplasmic reticulum (ER)-Golgi pathway of protein secretion in the release of ANXA1. The GC receptor antagonist,
RU486, neither reverted the Dex-dependent ANXA1 secretion nor inhibited the increase of the [Ca2+]
i
 induced by Dex. To-
gether, our results indicate that Dex induces ANXA1 synthesis and secretion in CCRF-CEM cells. ANXA1 secretion in this
cell type show the following characteristics: (i) is unlikely to involve the classical ER-Golgi pathway; (ii) requires a Ca2+-de-
pendent cleavage of ANXA1; (iii) involves both Ca2+-dependent and independent mechanisms; and (iv) is apparently inde-
pendent of the GC receptor alpha isoform. (Mol Cell Biochem 237: 31–38, 2002)
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Introduction
Annexin I (ANXA1) is a well-characterised member of a
structurally related family of Ca2+- and phospholipid-bind-
ing proteins [1, 2]. This protein has been implicated in cell
growth and differentiation [3–5], and in the initiation of mem-
brane fusion and exocytosis [6–8]. ANXA1 also appears to
mediate some of the anti-inflammatory actions of glucocorti-
coids (GCs), including inhibition of chemotaxis, and super-
oxide, prostaglandin and leukotrien production [9, 10].
Neutrophils and monocytes are particularly enriched in
ANXA1 and ANXA1 binding sites, and much attention has
been focused on the regulation of ANXA1 expression by GCs
in these cell types [11–14]. In contrast, the number of ANXA1
binding sites in lymphocytes is barely detectable, and whether
GCs regulate the expression of ANXA1 in these cells is still
a matter of debate [15–18]. Moreover, the expression of
ANXA1 and its regulation by steroids may also change dur-
ing the differentiation process [19–21]. Differentiated cells
are thought to constitutively express more ANXA1 than the
Address for offprints: M.C. Fernandes Lopes, Center for Neuroscience of Coimbra, Department of Zoology, University of Coimbra, 3004-517 Coimbra, Portugal
(E-mail: mcflopes@imagem.ibili.uc.pt)
32
undifferentiated cells [3, 22, 23]. Furthermore, the subcellu-
lar localisation of ANXA1 seems to depend on the cell type.
In different cells, ANXA1 has been detected in the cytosol,
bound to the plasma membrane or associated to the cytoskel-
eton [5, 6, 24].
Several in vivo and in vitro studies have shown that expo-
sure to endogenous or exogenous GC hormones increases the
cellular turnover of ANXA1, changes its subcellular locali-
sation and stimulates the secretion of this protein [3, 11, 16,
22, 24]. However, the mechanisms involved in ANXA1 ex-
portation from the intracellular milieu to the outer surface of
the plasma membrane are still not completely understood.
ANXA1 does not contain a hydrophobic signal sequence nec-
essary for the release from the intracellular compartment via
the classical endoplasmic reticulum (ER)-Golgi system, un-
like most proteins that undergo secretion [1, 25]. Some re-
cent studies suggest that its secretion occurs through an
unconventional pathway [2, 5, 11, 21], or through a Ca2+-
dependent mechanism [6, 7], both yet not totally understood.
Once outside the cell, ANXA1 gains access to specific high-
affinity, saturable and Ca2+-dependent binding sites [24, 26,
27], which have been clearly identified on the plasma mem-
brane of neuroendocrine and phagocytic cells [3, 15, 16,
18].
The aim of this study was to elucidate whether dexametha-
sone (Dex) modulates the secretion of ANXA1 in lymphocytes.
Furthermore, we also studied the roles of the intracellular free
Ca2+ concentration ([Ca2+]
i
) and of the GC receptor on the Dex-
induced ANXA1 secretion. For this purpose we used the hu-
man immature lymphoblastic cell line, CCRF-CEM, which we
previously showed to express ANXA1 [28]. We found that Dex
induced a Ca2+-dependent release of ANXA1, followed by de
novo synthesis of the protein in the lymphoblastic cells used.
Materials and methods
Culture conditions
The human T cell CCRF-CEM acute lymphoblastic leukemia
cell line (ATCC) was maintained in RPMI medium (Sigma
Chemical Co.) supplemented with 10% fetal calf serum (FCS)
(Biochrom), 100 µg/ml streptomycin and 100 U/ml penicil-
lin (Sigma Chemical Co.), at 37°C, in an atmosphere of 5%
CO
2
/95% air.
For experiments in which the effect of Dex on ANXA1 ex-
pression was determined, the cells were incubated with Dex
(Sigma Chemical Co.) (50 nM to 1 µM), for 30 min to 12 h.
The steroid antagonist RU486 (Sigma Chemical Co.) (1–10
µM) was used in the presence of Dex (1 µM), to study the
involvement of GC receptors.
For experiments in which the measurement of [Ca2+]
i
 was
the endpoint, the cells were incubated with Dex (1 µM), in
the presence and in the absence of RU486 (1–10 µM), for
30 min, 2 h or 4 h.
For experiments in which the secretion of ANXA1 was
studied, CCRF-CEM cells were incubated with Dex (1 µM)
in the presence or in the absence of brefeldin A (Sigma Chemi-
cal Co.) (1 µM to 1 mM), for 4 h. To determine the effect of
the [Ca2+]
i
 on ANXA1 secretion, CCRF-CEM cells were pre-
treated with BAPTA-AM (1,2-bis (o-aminophenoxy) ethane-
N,N,N′,N′-tetraacetic acid-acetoxymethyl ester) (Molecular
Probes) (10 µM), 30 min before the incubation with Dex
(1 µM), or with the Ca2+ ionophore, ionomycin (Molecu-
lar Probes) (3 µM), for 5–10 min.
All these experiments were performed with cells plated (1
× 106 cells/ml) in culture dishes and pre-incubated, for 14 h,
with RPMI supplemented with 2.5% FCS and antibiotics.
When CCRF-CEM cells were maintained in 10% FCS-sup-
plemented RPMI, they expressed a very high basal level of
ANXA1 that masked the effect exerted by Dex on protein
secretion (data not shown). In each experiment, controls
were always included by incubating the cells in the corre-
sponding volume of culture medium plus the appropriate
vehicle.
Viability of the CCRF-CEM cells was always checked by
the trypan blue exclusion and 3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyl tetrazolium bromide (MTT) (Sigma Chemical
Co.) reduction test prior to every experiment performed. As-
sessment of MTT reduction by metabolically active cells was
made by a colorimetric assay, as previously described [29,
30].
Western blot analysis
The secreted plasma membrane-bound ANXA1 was extracted
with 100 µl of phosphate buffer saline (PBS) containing 1 mM
ethylenediaminotetraacetic acid (EDTA), as previously de-
scribed [2, 31]. Cells were lysed in lysis buffer (10 mM Tris-
HCl, pH 7.6, 10% glycerol, 5 mM β-mercaptoethanol), and
a protease inhibitor cocktail (Roche) and then sonicated. Sam-
ples of cellular lysates (30 µg) and secreted proteins (2 µg)
were added (1:1) to denaturating buffer (200 mM Tris, 200 mM
bicine, 8 M urea, 4% SDS, 10% β-mercaptoethanol and 0.2%
bromophenol blue), boiled, subjected to 12% SDS-PAGE,
and electrotransferred to a PVDF (polyvinylidene difluoride)
membrane. The membrane was then blocked with 5% non-
fat dry milk in Tris-buffered saline (TBS) with 0.1% Tween
20. ANXA1 was detected by incubation with a mouse anti-
ANXA1 monoclonal antibody (BabCO) (2 µg/ml), followed
by incubation with a horseradish peroxidase-conjugated goat
anti-mouse antibody (Pierce). The immunocomplexes were
visualised by the ECL chemiluminescent method. To dem-
onstrate equivalent total protein loading, the membranes were
stripped with stripping buffer (100 mM β-mercaptoethanol,
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2% SDS, 62.5 mM Tris-HCl, pH 6.7), at 55°C, for 45 min.
After washing with TBS with 0.1% Tween 20, the membrane
was treated as indicated above, using the anti-actin mouse
monoclonal antibody (Roche) (0.1 µg/ml). The Ponceau S
and Indian Ink staining of the PVDF membrane was used to
show equivalent secreted protein loading.
Measurement of intracellular free Ca2+ concentration
In the final 30 min of each incubation with Dex, or RU486
plus Dex, the cells were loaded with fura-2/AM (Molecular
Probes) (3 µM). The cells were then rapidly washed by cen-
trifugation and resuspended in a Na+-salt solution (140 mM
NaCl, 5 mM KCl, 1 mM CaCl
2
, 1 mM MgCl
2
, 10 mM Glu-
cose, 10 mM Hepes). The Ca2+ measurements were per-
formed with 2 ml of cell suspension (1 × 106 cells) in a Perkin
Elmer LS-5B luminescence spectrometer, at a constant tem-
perature of 37°C. Excitation wavelength was 340 nm (5 nm
slit), and the emission wavelength was 510 nm (10 nm slit).
The [Ca2+]
i
 corresponding to fluorescence emitted by trapped
fura-2 was calculated by the equation: [Ca2+]
i
 = 224 nM × (F–
F
min
)/(F
max
–F); F
min
 = AF + (F
max
–AF)/3 (where 224 nM is the
K
d
 value for fura-2). F
max
 and AF (autofluorescence) were
obtained after the addition of ionomycin (3 µM) and MnCl
2
(2.25 mM), respectively, as previously described [32].
Statistical analysis
Results were expressed as means ± S.D. Comparison of data
from 2 treatment groups was made by the Student’s two-
tailed unpaired t-test. Comparison of data from more than 2
treatment groups was made by the one-way ANOVA analy-
sis with Dunnett’s post test. A probability of less than 5% (i.e.
p < 0.05) was taken as statistically significant.
Results
Effect of Dex on the intra and extracellular levels of
ANXA1
In order to test whether Dex influences the cellular content
of ANXA1 in the CCRF-CEM cell line, the cells were incu-
bated in the absence (control) or in the presence of different
concentrations of Dex (from 50 nM to 1 µM). Although Dex
appeared to influence the cellular ANXA1 content at 100 nM,
a significant, measurable and reproducible effect was only
observed with 1 µM Dex. Therefore, 1 µM Dex was the con-
centration used in all the experiments performed in this
work.
The ANXA1 externally bound to the plasma membrane can
be removed by washing the cells with a Ca2+-free salt solu-
tion, containing 1 mM EDTA, which by chelating Ca2+ releases
the extracellular ANXA1 into the medium, as previously de-
scribed [2, 31]. Therefore, the secreted ANXA1 was recov-
ered in the Ca2+-free salt solution used to wash the cells, and
the corresponding cellular lysates were used for the detec-
tion of intracellular ANXA1.
The Western blot analysis presented in Fig. 1 show that
treatment of the cells with Dex (1 µM), for 30 min or 4 h, de-
creased the level of intracellular ANXA1 to 50.7 ± 2.7 % and
48.4 ± 5.7%, respectively, of that found in control untreated
cells (p < 0.01). The intracellular content of ANXA1 was re-
stored, back to control levels (105.4 ± 2.1% relatively to the
control), by treatment of the cells with Dex, for 12 h.
The loss of intracellular ANXA1 is unlikely to be caused
by leakage of the protein from dead or damaged cells, as
the viability of the cells treated with Dex, for 30 min, 2, 4
or 12 h, was always > 95% relatively to control cells. The
cell viability was determined by the trypan blue exclusion
test and by the MTT assay (data not shown). Therefore, the
decrease in the cellular ANXA1 content, as shown in Fig.
1A, is likely to be due to a specific secretion of the intrac-
ellular protein.
The EDTA-extractable plasma membrane-bound ANXA1
defines the total amount of ANXA1 attached to the external
Fig. 1. Effect of Dex on the intracellular level of ANXA1. CCRF-CEM cells
were incubated in the absence (control, C) or presence of Dex (1 µM), for
30 min, 4 h or 12 h. ANXA1 externally bound to plasma membranes was
removed with an EDTA solution, as described in ‘Materials and methods’.
The intracellular ANXA1 content was determined by Western blot analy-
sis, using a mouse monoclonal anti-ANXA1 antibody (A), and the bands
were quantified with an image analyser (B). The data shown are an aver-
age of four independent experiments. The values are means ± S.D., where
**p < 0.01, as determined by one-way ANOVA with Dunnett’s post test.
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surface of the plasma membrane, and indirectly reflects the
amount of secreted ANXA1 [2, 31]. The results presented in
Fig. 2 indicate that stimulation of CCRF-CEM cells with Dex
(1 µM) increased the amount of plasma membrane-bound
ANXA1, reaching statistical significance after stimulation
with Dex for 4 and 12 h (206.1 ± 13.0 and 255.5 ± 18.0%
of control, respectively) (p < 0.01). The secreted ANXA1
appeared as a doublet of bands with 37 and 34 kDa (Fig.
2A).
The steroid antagonist, RU486, was used in order to de-
termine whether the effect of Dex on ANXA1 secretion could
be attributed to activation of GC receptors. RU486 (1–10 µM)
neither affected the amount of plasma membrane-bound
ANXA1 in the absence of Dex, nor did it revert, at any of the
concentrations used, the Dex-dependent secretion of ANXA1
in CCRF-CEM cells (data not shown).
To elucidate the mechanisms by which Dex stimulates the
secretion of ANXA1, we used brefeldin A (Bref A), which
blocks the classical endoplasmic reticulum-Golgi pathway of
protein secretion. For this purpose, CCRF-CEM cells were
treated with Dex (1 µM), for 4 h, in the absence or presence
of Bref A. The results presented in Fig. 3 show that Bref A,
in concentrations ranging from 1 µM to 1 mM, was unable
to inhibit the effect of Dex on the intracellular content of
ANXA1. However, in the presence of 1 mM Bref A the ob-
served effect of Dex was reverted, although incompletely.
Effect of Dex on the [Ca2+]
i
In order to evaluate whether Dex affects the [Ca2+]
i
 in the
CCRF-CEM cell line, the cells were incubated in the absence
(control) or presence of Dex (1 µM), and the [Ca2+]
i
 was as-
sessed using the fluorescent indicator fura-2. As shown in
Fig. 4, the level of [Ca2+]
i
 in control cells was 175.9 ± 13.0
nM, slightly increasing, after incubation with Dex (1 µM)
for 30 min, to 221.4 ± 16.1 nM. The [Ca2+]
i
 increased fur-
ther when the cells were exposed to Dex (1 µM) for 2 h (236.6
± 16.1 nM) or 4 h (210.1 ± 21.8 nM) (p < 0.05).
The steroid antagonist, RU486, was used to investigate the
putative role of GC receptors in the Dex-dependent [Ca2+]
i
rise. CCRF-CEM cells were incubated in the absence (control)
or presence of RU486 (10 µM) plus Dex (1 µM). The rise in
Fig. 2. Effect of Dex on the secretion of ANXA1. CCRF-CEM cells were
incubated in the absence (control, C) or presence of Dex (1 µM), for 30 min,
4 h or 12 h. Secreted plasma membrane-bound ANXA1 was extracted by
washing the cells with a Ca2+-free salt solution, containing 1 mM EDTA,
as described in ‘Materials and methods’. The secreted ANXA1 level was
determined by Western blot analysis, using a mouse monoclonal anti-
ANXA1 antibody (A), the PVDF membrane was stained with Indian Ink
(B), and both bands in each lane were quantified as one with an image ana-
lyser (C). The data shown are an average of 4 independent experiments.
The values are means ± S.D., where **p < 0.01 as determined by one-
way ANOVA with Dunnett’s post test.
Fig. 3. Effect of Bref A on the secretion of ANXA1. CCRF-CEM cells were
incubated without (control), or with Dex (1 µM) in the absence or presence
of Bref A (1 µM to 1 mM), for 4 h. ANXA1 externally bound to plasma
membrane was removed with an EDTA solution, as described in ‘Materi-
als and methods’. The intracellular ANXA1 content was determined by
Western blot analysis, using a mouse monoclonal anti-ANXA1 antibody
(A), and the bands were quantified with an image analyser (B). The data
shown are an average of 3 independent experiments. The values are means
± S.D., where **p < 0.01 and *p < 0.05, as determined by one-way ANOVA
with Dunnett’s post test.
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the [Ca2+]
i
 evoked by stimulation of the cells with Dex (1 µM),
in the presence of RU486 (10 µM), was not significantly dif-
ferent from that obtained in cells treated with Dex alone (data
not shown).
Effect of the [Ca2+]
i
 on ANXA1 secretion
Finally, we studied whether the effects of Dex on the secre-
tion of ANXA1 could be attributed to the increase in [Ca2+]
i
induced by this steroid. For this purpose, CCRF-CEM cells
were pre-loaded with the Ca2+ chelator BAPTA-AM, before
stimulation with Dex.
Treatment of the cells with Dex (1 µM), for 4 h, induced
an evident increase in the secreted ANXA1 (253.3 ± 21.8%
relatively to control) (p < 0.01), whereas, in the presence of
BAPTA, the amount of cell surface ANXA1 was dramatically
reduced, reaching levels equivalent to those found in control
untreated cells (Figs 5A and 5C). Additionally, analysis of the
corresponding intracellular extracts from cells pre-treated
with BAPTA-AM (10 µM) did not show differences relatively
to the control (Figs 5D and 5E).
To further elucidate the role of the [Ca2+]
i
 on ANXA1 secre-
tion induced by Dex, we used the Ca2+ ionophore ionomycin.
The results in Fig. 6 show that ionomycin (3 µM) by itself
induced no significant change in the level of intracellular
ANXA1, but it induced the appearance of both the 34 and
37 kDa ANXA1 bands which, after stimulation with Dex,
were detectable only in the extracellular fraction.
Fig. 4. Effect of Dex on the [Ca2+]i. CCRF-CEM cells were incubated in
the absence (control, C) or in the presence of Dex (1 µM), for 30 min, 2 h
and 4 h. The [Ca2+]i was measured using the fluorescent Ca
2+ indicator fura-
2, and the [Ca2+]i was calculated as described in ‘Materials and methods’.
The data shown are an average of 4 independent experiments. The values
are means ± S.D., where *p < 0.05 as determined by one-way ANOVA with
Dunnett’s post test.
Fig. 5. Effect of the [Ca2+]i on the secretion of ANXA1. CCRF-CEM cells
were incubated without (control, C), or with Dex (1 µM) in the absence or
presence of BAPTA-AM (10 µM), for 30 min, 2 h and 4 h. ANXA1 exter-
nally bound to plasma membranes was removed by washing the cells with
a Ca2+-free salt solution, containing 1 mM EDTA, as described in ‘Materi-
als and methods’. The secreted and the intracellular ANXA1 were deter-
mined by Western blot analysis using a mouse monoclonal anti-ANXA1
antibody (A, D), the PVDF membrane was stained with Indian Ink (B), and
the bands were quantified with an image analyser (C, E). The data shown are
an average of 3 independent experiments. The values are means ± S.D., where
**p < 0.01 as determined by one-way ANOVA with Dunnett’s post test.
Fig. 6. Effect of Ionomycin on the intracellular level of ANXA1. CCRF-
CEM cells were incubated in the absence (control) or presence of ionomycin
A (3 µM), for 10 min. ANXA1 externally bound to plasma membranes was
removed with an EDTA solution, as described in ‘Materials and methods’.
The intracellular ANXA1 content was determined by Western blot analy-
sis, using a mouse monoclonal anti-ANXA1 antibody (A), and the bands
were quantified with an image analyser (B).
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Discussion
Differentiated cells are thought to constitutively express more
ANXA1 than undifferentiated cells [3, 21, 22]. However ma-
ture lymphocytes express low amounts of ANXA1 and of
ANXA1 binding sites [15, 23, 33], and in our previous work
we observed that the immature lymphoblastic CCRF-CEM
cells express a considerable amount of intracellular ANXA1
[28]. In this work we found that Dex induces the secretion
of ANXA1 in this lymphoblastic cells by a Ca2+-dependent
mechanism.
In the absence of Dex, the bulk of ANXA1 was found in-
side the CCRF-CEM cells, and a small proportion of ANXA1
was associated with the outer surface of the plasma membrane
(Figs 1 and 2). Short periods (up to 4 h) of stimulation with
Dex caused a pronounced, and time-dependent, increase in
the plasma membrane-bound ANXA1 (Fig. 2), while the
intracellular ANXA1 level (non-extractable with Ca2+-free
medium) decreased to approximately 50% of that found in
control untreated cells (Fig. 1).
Expression of ANXA1 has been described as a process
dependent on the stage of cell differentiation. For example,
Dex increased ANXA1 synthesis and secretion only when U-
937 cells (an immature monocytic cell line) were differenti-
ated by treatment with phorbol 12-myristate 13-acetate [21,
34]. However, the results of this work show that the imma-
ture CCRF-CEM cells possess a Dex-dependent mechanism
of ANXA1 secretion, which is in accordance with most of the
previous studies in mature cells, including human neutrophils
and monocytes [11, 13, 35].
In several cell types, the reduction of the intracellular pool
of ANXA1, in response to Dex, is accompanied by de novo
synthesis of the protein [3, 24]. We found that stimulation
with Dex, for 12 h, induced a replenishment of the intracel-
lular content of ANXA1 (Fig. 1), and a significant increase
in the released protein (Fig. 2), indicating that in the lymphob-
lastic CCRF-CEM cell line Dex also upregulates ANXA1
synthesis.
Little is known about the mechanism by which ANXA1 is
secreted in response to GCs. ANXA1 has been reported to
lack the common hydrophobic signal sequence required for
the release via the ER-Golgi system [11]. Although, some
evidences indicate that ANXA1 secretion occurs through a
mechanism which culminates with exocytosis [2], others
found opposing evidence [5]. Since the classical ER-Golgi
pathway appears not to be involved in ANXA1 secretion [2,
11], an unknown alternative pathway is generally admitted.
Bref A reversibly blocks the anterograde transport of pro-
teins from the ER to the Golgi apparatus [2]. In contrast to
previous reports [2, 11], our results show that Bref A inhib-
ited the secretion of ANXA1 in response to Dex (Fig. 3).
However, those studies used micromolar concentrations of
Bref A [2, 11], whereas the inhibitory effect, observed in this
work, was only achieved with concentrations in the millimo-
lar range.
In different cells, micromolar concentrations of Bref A
blocked the classical ER-Golgi pathway preventing the se-
cretion of some proteins, but not ANXA1 [2]. Since micromo-
lar concentrations of Bref A are sufficient to inhibit classical
pathway of protein secretion, it is not likely that inhibition
of ANXA1 secretion occurred as a consequence of the block-
ade of that pathway. Instead, it is more likely that Bref A
blocked another pathway of protein secretion by a non-spe-
cific mechanism, which, consequently, required higher con-
centrations of this compound. On the other hand, Bref A did
not completely inhibit Dex-induced ANXA1 secretion. This
may suggest that Dex-induced ANXA1 secretion involves
another pathway that is not sensitive to Bref A. Nevertheless,
the lack of complete blockade of ANXA1 secretion may solely
reflect the involvement of a non-specific action of Bref A.
Taken together, our results suggest that the classical pathway
of protein secretion is not likely involved in Dex-induced
ANXA1 secretion in the lymphoblastic CCRF-CEM cells,
which is in agreement with studies in other cells [2, 11,
34]. Furthermore, our results also suggest that Dex-in-
duced ANXA1 secretion involve one or more , yet unidenti-
fied, secretory pathways which require high concentrations
of Bref A to be inhibited.
One possibility is that the process of secretion of ANXA1
is similar to that described for interleukin-1β, which involves
the proteolytic cleavage of a N-terminal peptide [2, 11, 21].
Indeed, our results show that following stimulation with Dex,
a 34 kDa species of ANXA1 is present in the extracellular
(secreted) fraction, together with the native 37 kDa form of
ANXA1. The appearance of both species of ANXA1 (34 and
37 kDa) in the extracellular medium has already been de-
scribed [31] and ANXA1 cleavage has been considered a
preliminary step for the secretion process [7, 25, 35]. Accord-
ingly, we found that only the full length ANXA1 (37 kDa) is
present in the intracellular fraction from Dex-treated cells
(Fig. 1), suggesting that all the cleaved protein was secreted.
Studies in neutrophils [6, 7] and HL-60 cells [36] suggest
that the secretion of ANXA1 may be attributed to an increase
in the [Ca2+]
i
. Furthermore, in monocytic cells, Dex has been
shown to increase the [Ca2+]
i
. This suggests that, in some cells,
Ca2+ signalling pathways may be involved in mediating the
cellular effects of Dex [37]. Accordingly, we found that Dex
caused a significant increase in the [Ca2+]
i
 in the lymphob-
lastic CCRF-CEM cells (Fig. 4). In order to investigate the
role of the Dex-induced increases in the [Ca2+]
i
 in ANXA1
secretion, we used the fast high affinity Ca2+ chelator, BAPTA.
The cell-permeant BAPTA-AM is converted by intracellular
esterases into BAPTA, which selectively buffers [Ca2+]
i
changes and depletes stores by direct Ca2+ binding [38]. We
found that the Dex-induced ANXA1 secretion was com-
pletely reverted by pre-treatment of the cells with BAPTA-
37
AM (Figs 5A and 5C), indicating that ANXA1 secretion
requires a rise of the [Ca2+]
i
. Furthermore, the results on Fig.
5 D show that only the full length ANXA1 (37 kDa) is present
in the intracellular fraction of cells treated with BAPTA-AM
and Dex.
In order to further elucidate the role of the [Ca2+]
i
 on the
ANXA1 secretion, we used the Ca2+ ionophore, ionomycin
(Fig. 6). The results obtained show that ionomycin did not
reduce the total intracellular content of the protein. Never-
theless, the elevation of the [Ca2+]
i
 induced by ionomycin,
was sufficient for the cleavage of ANXA1 to occur, since both
the 34 and 37 kDa species were found in the intracellular
fraction (Fig. 6 A). These results indicate that, in the lymphob-
lastic cells used, the cleavage of ANXA1 is a Ca2+-depend-
ent mechanism, which is in accordance with previous studies
in neutrophils [7].
Taken together, the results obtained with the Ca2+ chelator
BAPTA and with the Ca2+ ionophore ionomycin, suggest that
ANXA1 cleavage is a Ca2+-dependent process, which is es-
sential for and precedes ANXA1 secretion. Nevertheless,
although required for the cleavage of ANXA1, the increased
[Ca2+]
i
 is not sufficient for the secretion of the protein, since
ionomycin alone did not decrease the intracellular levels of
ANXA1 (Fig. 6). Therefore, besides this Ca2+-dependent sig-
nalling pathway, other intracellular processes have to be acti-
vated by Dex, in lymphoblastic cells, so that ANXA1 secretion
can be accomplished.
The effects of Dex on ANXA1 secretion and on changes
of the [Ca2+]
i
 in different cells have been attributed to the
activation of GC receptors [2, 22, 39, 40]. Several evidences
show that RU486, a potent GC receptor antagonist, has been
commonly used to study the involvement of GC receptors on
the expression of annexin 1 induced by GCs [1, 3, 22, 39].
Therefore, in this work we used RU486 to investigate whether
the effects of Dex reported here were mediated by the GC
receptor. Although CCRF-CEM cells constitutively express
the intracellular GC receptor alpha isoform, RU486 (10 µM),
failed to inhibit the effect of Dex on the [Ca2+]
i
 and on
ANXA1 secretion (data not shown), suggesting that these
receptors unlikely mediate the effects of Dex reported here.
On the other hand, these effects of Dex were only consistent
and significant when high concentrations (1 µM) of Dex were
used. This also argues against the involvement of the GC
receptor, since ligand-receptor interactions usually occur
with much lower concentrations. However, we observed
that concentrations of RU486 higher than 10 µM were toxic
to the cells (viability < 70% relatively to control cells) (data
not shown), which limited the possibility of further eluci-
dating the involvement of the GC receptor in the responses
induced by Dex. Therefore, we cannot definitely exclude
the involvement of the intracellular GC receptor alpha iso-
form in ANXA1 secretion. However, other studies showed
that the effects of Dex may occur through RU486-insensi-
tive GC plasma membrane binding sites [40] that have been
previously described in CCRF-CEM cells [41], and/or via
non-genomic mechanisms, such as the mitogen-activated
protein kinases [42] or protein kinase C [43, 44].
In summary, our results indicate that Dex induces the syn-
thesis and secretion of ANXA1 in the human immature lym-
phoblastic CCRF-CEM cells, and that Dex-induced ANXA1
secretion results from the combination of several processes,
each of which is essential, but not sufficient, for ANXA1
secretion to be accomplished.
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